Navigation Links
Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
Date:9/15/2011

TARRYTOWN, N.Y., Sept. 15, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Science magazine has ranked Regeneron as the #2 employer in the global biopharmaceutical industry in its annual survey of Top Employers.

"It is extremely satisfying for Regeneron to be recognized by Science as one of the best  places to be a scientist," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "It is a priority at Regeneron to create an environment where talented individuals can conduct groundbreaking science and where creativity and innovation are encouraged and recognized.  We are grateful to Science for acknowledging our science-based culture and to our fantastic employees who give their best every day to the pursuit of important new medicines through scientific discoveries."

Details of the rankings and survey results will be published online on Sept. 16 at www.sciencecareers.org/TopEmployers2011 and will be included in the Oct. 7 print issue of Science.

Regeneron, founded in 1988, currently has approximately 1,670 employees, of whom more than 300 hold Ph.D. or M.D. degrees.  Regeneron has added about 1,000 employees since 2007, primarily to support its research and development programs.  The Company proprietary VelociGene® and VelocImmune® technologies were used to discover and develop eight fully-human monoclonal antibodies that are in clinical development.  The Company's Trap fusion protein technology was applied to develop ARCALYST® (rilonacept) and two product candidates that have completed Phase 3 clinical studies.

About the Top Employers SurveyThe Science and Science Careers' annual Top Employers Survey polls employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the driving characteristics of the best employers and to identify the 20 best employers from a universe of about 200 companies.  Respondents to the web-based survey were asked to rate companies based on 23 characteristics, including financial strength, easy adaptation to change, and a research-driven environment.

According to Science, the 2011 global survey results were based on 3,784 responses from North America (80%), Europe (12%), and Asia/Pacific Rim (6%).  A mathematical process was used to assign a unique score to rate each company's employer reputation.

About Regeneron Pharmaceuticals Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufacturers, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is approved for the treatment of a rare inflammatory condition, Regeneron has completed Phase 3 clinical trials of rilonacept for a new indication and of product candidates EYLEA™ (aflibercept injection; VEGF Trap Eye) in diseases of the eye and ZALTRAP® (aflibercept) (VEGF Trap) in colorectal cancer.  EYLEA is currently under review with U.S. and European regulatory authorities.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on www.regeneron.com.Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7640michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
2. Regeneron Reports Second Quarter 2011 Financial and Operating Results
3. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
4. Trading in Regeneron Common Stock Halted
5. Regeneron Reports First Quarter 2011 Financial and Operating Results
6. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
7. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
8. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
9. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
10. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
11. Regeneron Announces March 2011 Investor Conference Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 2016 Hutchison China MediTech ... on the highly lucrative global oncology and immunology ... potential first-in-class or best-in-class tyrosine kinase inhibitor (TKI) ... strategic partners. HCM,s profitable Chinese healthcare business continues ... expect progress of the mid-to-late-stage pipeline during 2016-17 ...
(Date:5/26/2016)... , May 26, 2016 A ... growth is the emergence of new treatments. Cardax, a ... for osteoarthritis treatment. The therapy is expected to fulfil ... Research UK is conducting studies to develop new treatments ... where the genes involved in osteoarthritis are being investigated, ...
(Date:5/25/2016)... , May 25, 2016 According ... by Type (3D, 2D, 4D), by Therapeutic Area (Oncology, ... End User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast ... global Medical Animation Market for the forecast period of ... USD 301.3 Million by 2021 from USD 117.3 Million ...
Breaking Medicine Technology:
(Date:5/27/2016)... , ... May 27, 2016 , ... Aimed at nurses ... interest stories, which come courtesy of leaders in the nursing and health care industry. ... leading advocates and associations—namely Abilene Christian University. , As the nursing industry is ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways ... and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight off the grill. ... say grilling is their favorite way to cook a hot dog, far outpacing other ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... (IP) to its specialty academic programs. , Answering to the increasing demand for ... programs in health law, and environmental and land use law. ,  , “The ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
(Date:5/26/2016)... ... 26, 2016 , ... Dr. James Maisel will present on ... Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public Library. The ... Group of New York , is a Board Certified ophthalmologist who completed his ...
Breaking Medicine News(10 mins):